New York, June 15, 2023 (GLOBE NEWSWIRE) — June 15, 2023 — CureDuchenne, Muscular Dystrophy Association (MDA), and Parent Project Muscular Dystrophy (PPMD), today announced a collaborative clinical trial grant to test repurposing of the FDA-approved drug Vyvgart (developed by argenx), for its potential ability to reduce antibodies to adeno-associated…Read More
CureDuchenne Muscular Dystrophy Association and Parent Project Muscular Dystrophy Announce Collaborative Project to Focus on ReDosing Gene Therapy in Duchenne Muscular Dystrophy
